NCT01109121View on ClinicalTrials.gov

Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)

PHASE2CompletedINTERVENTIONAL

Enrollment

112

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

January 31, 2011

Conditions

Moderate to Severe GoutHyperuricemia

Interventions

DRUG

Combination 400

Tranilast 300 mg QD; Allopurinol 400 mg QD

DRUG

Allopurinol

Allopurinol 400 mg, QD

DRUG

Combination 600

Tranilast, 300 mg QD; Allopurinol 600 mg QD

Trial Locations (24)

Unknown

Nuon Investigative Site, La Jolla

Nuon Investigative Site, Santa Maria

Nuon Investigative Site, Washington D.C.

Nuon Investigative Site, New Port Richey

Nuon Investigative Site, Honolulu

Nuon Investigative Site, Boise

Nuon Investigative Site, Bloomington

Nuon Investigative Site, Owensboro

Nuon Investigative Site, Baltimore

Nuon Investigative Site, Wheaton

Nuon Investigative Site, Billings

Nuon Investigative Site, Omaha

Nuon Investigative Site, Reno

Nuon Investigative Site, Teaneck

Nuon Investigative Site, Durham

Nuon Investigative Site, Cincinnati

Nuon Investigative Site, Oklahoma City

Nuon Investigative Site, Lake Oswego

Nuon Investigative Site, Duncansville

Nuon Investigative Site, West Reading

Nuon Investigative Site, Charleston

Nuon Investigative Site, Greenville

Nuon Investigative Site, Waco

Nuon Investigative Site, Spokane

Sponsors

Lead Sponsor

Nuon Therapeutics, Inc.

All Listed Sponsors

lead

Nuon Therapeutics, Inc.

INDUSTRY